Muscle & Recovery Research Stack

$259.00

In stock
COA-verified
≥99% purity.
USA manufactured.
In stock
COA-verified
≥99% purity.
USA manufactured.
COA-verified
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.
In stock
≥99% purity.
USA manufactured.

What Is Muscle & Recovery Research Stack

A laboratory research stack focused on GH/IGF-axis signaling, growth-factor receptor biology, skeletal-muscle models, connective-tissue response, and cell-migration pathways.

COMPONENT

CJC-1295 + Ipamorelin (Blend)

IGF-1 LR3

BPC-157 + TB-500 (Blend)

QUANTITY

5mg/5mg

1mg

10mg/10mg

RESEARCH CLASS

GHRH and ghrelin-receptor secretagogue research

long-acting IGF-1 analog research

soft-tissue and cell-migration research blend

The Muscle & Recovery Research Stack combines two premixed research blends and one growth-factor analog. CJC-1295 is a long-acting GHRH analog, while ipamorelin is a selective growth hormone secretagogue receptor agonist used in GH-release studies. IGF-1 LR3 is a modified IGF-1 analog with reduced binding to IGF-binding proteins and an extended experimental activity profile. The BPC-157 + TB-500 blend is used in preclinical soft-tissue, vascular, and cell-migration research.
These compounds act through different molecular systems. The stack is supplied for controlled laboratory research only, and no combined effect or compatibility is established.

GHRH receptor and ghrelin-receptor signaling studies
Growth hormone pulse and downstream IGF-axis pathway modeling
IGF-1 receptor activation and skeletal-muscle cell research
Tendon, ligament, vascular, and connective-tissue experimental models
Actin dynamics, fibroblast migration, and extracellular-matrix response

CJC-1295 was developed as a stabilized GHRH analog capable of prolonged GH-axis stimulation. Ipamorelin emerged from growth hormone secretagogue research as a comparatively selective ghrelin-receptor agonist. IGF-1 LR3 was engineered to extend experimental persistence and reduce binding-protein interactions. BPC-157 and thymosin beta-4-derived compounds were developed through separate preclinical programs examining tissue-response mechanisms.

Reserch-grade coenzyme compound visualization.

COMPOUND

CJC-1295 + Ipamorelin + IGF-1 LR3 + BPC-157 + TB-500

TYPE

Multi-component growth factor and connective tissue research stack

MOLECULAR FORMULA

Not applicable (multi-component formulation)

MOLECULAR WEIGHT

Not applicable (individual component molecular weights vary)

PURITY

≥99%

ANALYSIS

HPLC Verified

STORAGE

Store at -20°C. Protect from light and moisture.

CLASSIFICATION

Reserch Use Only

Research Findings

Published and preclinical research relevant to the individual components covers several areas of scientific investigation, including:

GH secretagogue research: CJC-1295 and ipamorelin are studied for GHRH- and ghrelin-receptor-mediated GH release.
IGF signaling research: IGF-1 LR3 is used to evaluate IGF-1 receptor signaling, cell growth, differentiation, and protein-turnover pathways.
Soft-tissue models: BPC-157 research examines vascular and connective-tissue response, while thymosin beta-4 research examines actin dynamics and cell migration.
Comparative pathway design: The stack allows separate investigation of endocrine signaling, direct growth-factor signaling, and tissue-response pathways.

References

1. Teichman SL, et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536

2. Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552

3. Clemmons DR. (2007). Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature Reviews Drug Discovery, 6, 821–833. https://doi.org/10.1038/nrd2359

4. Goldstein AL, Hannappel E, Kleinman HK. (2012). Thymosin beta4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 12(1), 37–51. https://doi.org/10.1517/14712598.2012.634793

FAQ

What type of research is this stack used for?

Muscle & Recovery Research Stack is intended for controlled in vitro, analytical, and preclinical laboratory research involving the pathways described on this page. Experimental design should address each component independently.

Where is BioRhex’s Muscle & Recovery Research Stack manufactured?

All BioRhex compounds included in this stack are manufactured in a GMP-compliant facility located in the United States.

What testing does BioRhex conduct on the included compounds?

Each applicable batch undergoes third-party HPLC purity testing, mass spectrometry identity verification, and sterility testing. Batch-specific Certificates of Analysis are included or made available for the individual components.

Does the stack have one molecular formula or one Certificate of Analysis?

No. A stack contains multiple independent compounds. Each component has its own molecular identity, batch number, test results, and Certificate of Analysis.

Is this stack approved for human use?

No. The compounds in this stack are not supplied for human or animal administration. They are provided exclusively for laboratory research purposes.

All BioRhex compounds in the Muscle & Recovery Research Stack are supplied strictly for laboratory research purposes. Not for human or animal consumption, medical use, diagnostic use, or therapeutic application. The compounds are not represented as FDA-approved for the uses described on this page. Nothing in this document should be interpreted as health guidance, dosage guidance, or a recommendation for use outside controlled research settings.